Sitemap

December 29, 2013 Articles

Filter by Available Specialty
  1. DAWN2: Only 29% patients asked for input on diabetes treatment
  2. Electronic death records effective influenza surveillance tool
  3. Evolocumab effectively reduced LDL in phase 3 trial
  4. Zimmer Holdings appoints new board of directors member